Pliant Therapeutics, Inc. (PLRX)
NASDAQ: PLRX · IEX Real-Time Price · USD
14.18
-0.11 (-0.77%)
Nov 27, 2023, 4:00 PM EST - Market closed
Pliant Therapeutics Revenue
Pliant Therapeutics had revenue of $3.55M in the twelve months ending September 30, 2023, down -63.53% year-over-year. In the year 2022, Pliant Therapeutics had annual revenue of $9.69M with 27.91% growth.
Revenue (ttm)
$3.55M
Revenue Growth
-63.53%
P/S Ratio
239.58
Revenue / Employee
$22,296
Employees
159
Market Cap
849.33M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2022 | 9.69M | 2.11M | 27.91% |
Dec 31, 2021 | 7.57M | -34.25M | -81.89% |
Dec 31, 2020 | 41.82M | -15.24M | -26.70% |
Dec 31, 2019 | 57.05M | - | - |
Dec 31, 2018 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Collegium Pharmaceutical | 546.64M |
Phreesia | 319.36M |
Paragon 28 | 207.34M |
REGENXBIO | 99.37M |
Alpine Immune Sciences | 30.80M |
Editas Medicine | 24.61M |
Viridian Therapeutics | 347.00K |
PLRX News
- 14 days ago - Pliant Therapeutics Presentations at The Liver Meeting® 2023 Highlight Bexotegrast, an Inhibitor of αvß6 and αvß1 Integrins, in Primary Sclerosing Cholangitis - GlobeNewsWire
- 18 days ago - Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results - GlobeNewsWire
- 19 days ago - Pliant Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 21 days ago - Pliant Therapeutics Presentations at the Annual Meeting of the Society for Immunotherapy of Cancer Highlight PLN-101095, A Novel Inhibitor of Integrins αvβ8 and αvβ1 - GlobeNewsWire
- 27 days ago - Pliant Therapeutics Announces Three Presentations at the Annual Meeting of the Society for Immunotherapy of Cancer - GlobeNewsWire
- 5 weeks ago - Pliant Therapeutics INTEGRIS-PSC Phase 2a Interim Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in an Oral Late-Breaking Presentation at The Liver Meeting® 2023 - GlobeNewsWire
- 6 weeks ago - Pliant Therapeutics Appoints S. Mishima Gerhart as Chief Regulatory Officer - GlobeNewsWire
- 2 months ago - Pliant Therapeutics shares surge as liver-disease treatment shows promise in clinical trial - Market Watch